Equity Rights Offering	6 Months Ended
Jun. 30, 2025
Warrants and Rights Note Disclosure [Abstract]
Equity Rights Offering	Note 11 – Equity Rights Offering In September 2020, the Corporation completed an equity rights offering, issuing 5,507,889 shares of its common stock and 12,339,256 Series A warrants to existing shareholders. The shares of common stock and warrants are classified as equity instruments in the condensed consolidated statements of shareholders’ equity. Each Series A warrant provided the holder with the right to purchase 0.4464 shares of common stock at an exercise price of $2.5668, or $5.75 per whole share of common stock. During 2025, including warrants exercised in the third quarter of 2025 prior to expiration, 6,114 of warrants were exercised including 5,715 warrants exercised in the third quarter of 2025. The remaining 10,935,755 outstanding Series A warrants expired August 1, 2025 and are no longer exercisable, in accordance with the warrant agreement.

Equity Rights Offering

6 Months Ended

Jun. 30, 2025

Warrants and Rights Note Disclosure [Abstract]

Note 11 – Equity Rights Offering

In September 2020, the Corporation completed an equity rights offering, issuing 5,507,889 shares of its common stock and 12,339,256 Series A warrants to existing shareholders. The shares of common stock and warrants are classified as equity instruments in the condensed consolidated statements of shareholders’ equity. Each Series A warrant provided the holder with the right to purchase 0.4464 shares of common stock at an exercise price of $2.5668, or $5.75 per whole share of common stock. During 2025, including warrants exercised in the third quarter of 2025 prior to expiration, 6,114 of warrants were exercised including 5,715 warrants exercised in the third quarter of 2025. The remaining 10,935,755 outstanding Series A warrants expired August 1, 2025 and are no longer exercisable, in accordance with the warrant agreement.